All In Biotech

Drug Trial Radar · NCT05662306

C-Cog in Early Course Schizophrenia Study

Comprehensive Treatment of Early Course Schizophrenia: A Nonrandomized Study of Long Acting Injectable Antipsychotic Medication Combined With Cognitive and Functional Skills Training

Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

1

Actual

Start

Jan 23, 2024

Primary completion

Mar 3, 2025

Study completion Mar 3, 2025

Sponsor

Lead sponsor
University of MiamiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alkermes, Inc.
First posted
Dec 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • Aripiprazole LauroxilDrug

    1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.

  • Computerized cognitive and functional skills trainingBehavioral

    Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage of Participants Who Develop Sustained Remission of Symptoms of Schizophrenia as Measured as Having a Score of 3 or Less on All 6 Critical Items From the Positive and Negative Syndrome Scale (PANSS)Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jackson Memorial Hospital

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.